What are the latest evidence‑based first‑line and subsequent treatment recommendations for extensive‑stage and limited‑stage small cell lung cancer, including platinum‑based chemotherapy combined with immune‑checkpoint inhibitors (atezolizumab or durvalumab), consolidation therapy, second‑line options such as lurbinectedin, topotecan, or cyclophosphamide/daunorubicin/vincristine (CAV), and the role of prophylactic cranial irradiation?

Latest Updates to Small Cell Lung Cancer Treatment

The most significant recent advance in SCLC treatment is the addition of immune checkpoint inhibitors (atezolizumab or durvalumab) to platinum-based chemotherapy for extensive-stage disease, and durvalumab consolidation for limited-stage disease after chemoradiotherapy, both now representing standard-of-care with Category 1 evidence.

Extensive-Stage SCLC: First-Line Treatment

Preferred Regimen (Category 1)

For treatment-naïve extensive-stage SCLC patients with good performance status (ECOG 0-1) and no contraindications to immunotherapy, combine platinum-etoposide chemotherapy with either atezolizumab or durvalumab, followed by maintenance immunotherapy 1, 2, 3.

Atezolizumab Regimen

• Induction: Carboplatin (AUC 5) + etoposide (100 mg/m²) + atezolizumab (1200 mg) every 3 weeks for 4 cycles
• Maintenance: Atezolizumab 1200 mg every 3 weeks (Category 1) or 1680 mg every 4 weeks (Category 2A) until progression 1, 4
• Survival benefit: Median OS 12.3 months vs 10.3 months with chemotherapy alone (HR 0.70); 18-month OS 34% vs 21% 2

Durvalumab Regimen

• Induction: Carboplatin or cisplatin + etoposide + durvalumab (1500 mg) every 3 weeks for 4 cycles
• Maintenance: Durvalumab 1500 mg every 4 weeks until progression 1, 5
• Survival benefit: Median OS 13.0 months vs 10.3 months (HR 0.73); 3-year OS rate improved 1
• Note: Adding tremelimumab to durvalumab did NOT improve outcomes 2

For Immunotherapy-Ineligible Patients

• Standard: 4-6 cycles of platinum (cisplatin or carboplatin) + etoposide 2
• Carboplatin may substitute cisplatin, though cisplatin preferred in younger patients (<70 years) with good PS 2

Consolidation Therapy Considerations

• Thoracic radiotherapy: 30 Gy in 10 fractions may be offered to responders with PS 0-2 2
• Prophylactic cranial irradiation (PCI):
  • 25 Gy in 10 fractions for patients <75 years with response and PS 0-2 2
  • May be omitted if brain MRI negative post-chemotherapy and regular MRI surveillance feasible 2
  • Role uncertain when combined with immunotherapy—use shared decision-making 2

Limited-Stage SCLC: Major Update

Concurrent Chemoradiotherapy

• Standard: Concurrent platinum-etoposide with thoracic radiotherapy 6, 2, 6
• Preferred radiation: 45 Gy twice-daily in 30 fractions, starting cycle 1-2 of chemotherapy 6, 2
• Sequential chemoradiotherapy acceptable if concurrent not feasible due to PS or disease volume 2

NEW: Durvalumab Consolidation (ADRIATIC Trial)

Following concurrent chemoradiotherapy without progression, durvalumab consolidation (1500 mg every 4 weeks for up to 2 years) is now recommended 7, 3, 5.

• Landmark improvement: Median OS approximately 22 months 8
• Eligibility: PS 0-1 (strong recommendation); PS 2 may be considered if improvement occurs 7, 3
• This represents the most significant advance in limited-stage SCLC in decades

Prophylactic Cranial Irradiation

• Recommended: 25 Gy in 10 fractions for responders with PS 0-1 6, 2
• Less defined role in stage I-II disease or patients >70 years—use shared decision-making 2

Second-Line and Relapsed Disease

NEW: Tarlatamab (FDA-Approved 2024)

For patients progressing after ≥2 prior systemic regimens (including platinum), tarlatamab represents a novel bispecific T-cell engager targeting DLL3 7, 8.

Dosing and Efficacy

• Regimen: 1 mg IV day 1, then 10 mg days 8 and 15 of cycle 1, then 10 mg every 2 weeks 7
• Response rate: 40% overall; 52% in platinum-resistant disease 7
• Median PFS: 4.9 months; median duration of response: 9.7 months 7
• Survival: OS 13.6 months vs 8.3 months with standard chemotherapy 8

Unique Toxicities

• Cytokine release syndrome (CRS): 51% (mostly grade 1-2,1% grade 3); median onset 13 hours 7
• ICANS: 8% (all grade 1-2) 7
• Requires: 24-hour inpatient monitoring after first two doses 7

Platinum-Sensitive Relapse (Chemotherapy-Free Interval ≥90 Days)

Rechallenge with platinum-etoposide OR single-agent therapy (topotecan, lurbinectedin, or tarlatamab) 7, 3.

Platinum-Resistant/Refractory (<90 Days)

Preferred single agents 2, 7, 3:

1. Topotecan (oral or IV)
2. Lurbinectedin (54.8% response rate in heavily pretreated patients; FDA Breakthrough designation) 2, 8
3. Tarlatamab (preferred for ≥2 prior lines) 7
4. CAV (cyclophosphamide/doxorubicin/vincristine) as alternative 2

Critical Caveat: Immunotherapy Continuation

Do NOT continue immunotherapy in patients progressing on maintenance immunotherapy—no evidence supports this practice 3.

Emerging Targeted Therapies

B7-H3 (CD276) Targeting

Ifinatamab deruxtecan (antibody-drug conjugate):

• 54.8% response rate in heavily pretreated patients 8
• FDA Breakthrough designation 8
• Uniformly expressed across SCLC subtypes 8

Molecular Subtyping

Four transcriptional subtypes identified (SCLC-A, -N, -P, -I):

• SCLC-I (inflammatory) appears more responsive to immune checkpoint inhibitors 8
• May guide future personalized approaches, though not yet standard practice 8

Key Clinical Pitfalls to Avoid

1. Do not delay chemotherapy waiting for radiation therapy to start in limited-stage disease 9, 3

2. Do not use concurrent immunotherapy with chemoradiotherapy in limited-stage SCLC outside clinical trials—give durvalumab as consolidation AFTER chemoradiotherapy 7, 3

3. Do not continue checkpoint inhibitors beyond progression on maintenance therapy 3

4. Do not use multiagent chemotherapy in relapsed disease—single agents preferred due to toxicity concerns 7, 3

5. PCI decision-making: Consider omitting if negative brain MRI and reliable surveillance possible, especially with immunotherapy exposure 2

6. Tarlatamab requires specialized monitoring for CRS/ICANS—ensure 24-hour observation capacity for initial dosing 7

Treatment Algorithm Summary

Extensive-Stage:

• 1st-line: Platinum-etoposide + atezolizumab OR durvalumab → maintenance immunotherapy
• Relapse ≥90 days: Rechallenge platinum-etoposide OR single agent (topotecan/lurbinectedin/tarlatamab)
• Relapse <90 days: Single agent (topotecan/lurbinectedin/tarlatamab preferred)
• ≥2 prior lines: Tarlatamab strongly preferred

Limited-Stage:

• Concurrent: Platinum-etoposide + twice-daily thoracic RT (45 Gy)
• Consolidation: Durvalumab 1500 mg every 4 weeks × 2 years (NEW standard)
• PCI: 25 Gy/10 fractions if response and PS 0-1